Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2020
Health Canada approves Zeposia, an oral treatment for relapsing remitting multiple sclerosis
7 October 2020 - Bristol Myers Squibb's medication provides a new oral treatment option for Canadians living with the neurological disease. ...
Posted by Michael Wonder on 08 Oct 2020
Inaugural Chief Advisor, Māori appointed to PHARMAC
8 October 2020 - “PHARMAC is committed to upholding the articles of te Tiriti o Waitangi across all areas of ...
Posted by Michael Wonder on 08 Oct 2020
Donald Trump back in Oval Office, pledges drugs he got to all for free
8 October 2020 - Donald Trump has hailed treatment he received for COVID-19 as a “cure”, pledging to make it ...
Posted by Michael Wonder on 07 Oct 2020
European countries face shortages of COVID-19 drug remdesivir
7 October 2020 - European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, ...
Posted by Michael Wonder on 07 Oct 2020
NICE terminates yet another appraisal
7 October 2020 - 9 of the last 20 published technology appraisals have been terminated. ...
Posted by Michael Wonder on 07 Oct 2020
Double dippers drive up drug costs
7 October 2020 - In searching for answers to why drug costs are high, we only need look at problems ...
Posted by Michael Wonder on 07 Oct 2020
Implementation of Stage 2 PBS process improvements from 1 January 2021
7 October 2020 - As announced by Government in the 2020-21 Budget, Stage 2 PBS process improvements will commence from ...
Posted by Michael Wonder on 07 Oct 2020
Eton Pharmaceuticals submits new drug application to the FDA for topiramate oral solution
6 October 2020 - Application submitted for the treatment of partial-onset seizures and migraine. ...
Posted by Michael Wonder on 07 Oct 2020
PHARMAC confirms their new way of contracting for medicines
7 October 2020 - PHARMAC is standardising the way medicines are contracted, providing better support to health care professionals when ...
Posted by Michael Wonder on 07 Oct 2020
Oncternal Therapeutics receives rare paediatric disease designation from U.S. FDA for TK216 for treatment of Ewing sarcoma
6 October 2020 - Oncternal Therapeutics today announced that the U.S. FDA has granted rare paediatric disease designation for TK216, an ...
Posted by Michael Wonder on 07 Oct 2020
Aegle Therapeutics receives rare paediatric disease designation from the FDA for AGLE-102 for patients with dystrophic epidermolysis bullosa
6 October 2020 - -- Aegle Therapeutics today announced that the FDA has granted rare paediatric disease designation to ...
Posted by Michael Wonder on 06 Oct 2020
ISPOR’s real world evidence transparency initiative: creating a road map that builds trust
5 October 2020 - Transparency of Data, Methods, Analyses, and Results Will Increase Confidence in Study Credibility. ...
Posted by Michael Wonder on 06 Oct 2020
Next-generation wet AMD therapy Beovu, now available in Canada, receives positive recommendation from CADTH Drug Expert Committee
5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu. ...
Posted by Michael Wonder on 06 Oct 2020
Supreme Court wary of letting states regulate prescription drug 'middlemen'
6 October 2020 – The Supreme Court appeared skeptical Tuesday that states should be allowed to regulate prescription drug "middlemen," ...
Posted by Michael Wonder on 06 Oct 2020
Department publishes yet another revised agenda for November PBAC meeting
6 October 2020 - This time it is an addition of a late agenda item. ...